| Category |
Surgery |
| Manuscript Type |
Retrospective Study |
| Article Title |
Prognostic impact of neoadjuvant therapy vs upfront surgery in patients with huge hepatocellular carcinoma undergoing curative resection
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Meng-Ran Lang, Ru-Yu Han, Feng-Yi Zhu, Zhi-Hao Wang, Jian-Xin Zhai, Man Luo, Yao-Wei Hu, Chang-Cheng Tao, Ta-Na Siqin, Ji Sun, Zhi-Yu Lu, Jian-Jun Zhao, Jun-Xiang Tong, Xun Wang, Da-Yong Cao, Li-Ming Wang, Wei-Qi Rong, Jian-Xiong Wu, Xuan Meng and Hong-Guang Wang |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82473496 |
| National Natural Science Foundation of China |
82272963 |
|
| Corresponding Author |
Hong-Guang Wang, Department of Hepatobiliary Surgery, National Cancer Center/National Clinical, Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, Beijing 100020, China. wanghongguang1972@163.com |
| Key Words |
Hepatocellular carcinoma; Huge hepatocellular carcinoma; Neoadjuvant therapy; Liver resection; Recurrence-free survival |
| Core Tip |
Huge hepatocellular carcinoma (HCC) is a particularly aggressive form of liver cancer, and surgery alone often fails to prevent early recurrence. Whether treatment before surgery can improve outcomes in these patients remains unclear. In this retrospective study, we compared patients with huge HCC who underwent surgery after neoadjuvant therapy with those who received upfront surgery. Neoadjuvant therapy was associated with better recurrence-free and overall survival, without significantly increasing operative time, blood loss, transfusion, or postoperative hospital stay. The benefit appeared to be greater in patients with aggressive disease features such as vascular invasion, portal vein tumor thrombus, and Barcelona Clinic Liver Cancer stage C disease. These findings suggest that multimodal neoadjuvant therapy may be a useful perioperative strategy for selected patients with huge HCC and warrant further prospective validation. |
| Citation |
Lang MR, Han RY, Zhu FY, Wang ZH, Zhai JX, Luo M, Hu YW, Tao CC, Siqin TN, Sun J, Lu ZY, Zhao JJ, Tong JX, Wang X, Cao DY, Wang LM, Rong WQ, Wu JX, Meng X, Wang HG. Prognostic impact of neoadjuvant therapy vs upfront surgery in patients with huge hepatocellular carcinoma undergoing curative resection. World J Gastroenterol 2026; In press
|
